La sclérose tubéreuse de Bourneville (STB) est une maladie génétique et multi-systémique à transmission autosomique dominante due à des mutations d’un gène TSC1 ou TSC2 qui codent respectivement pour hamartine et tuberine ayant une action inhibitrice sur la voie de signalisation mTOR. L’épilepsie précoce et pharmacorésistante est la manifestation neurologique la plus fréquente et la plus délétère de la STB. Elle débute souvent dans la première année de vie par des spasmes infantiles qui évoluent avec l’âge et en absence de traitement vers des crises toniques ou tonico-cloniques. Bien que les crises soient supposées être générées dans des tubers corticaux, les mécanismes de l’épilepsie ne sont pas bien élucidés et le traitement reste souvent inefficace. Des études morphologiques ont montré une altération de l’expression ARNm des récepteurs au glutamate dans les cellules géantes et les neurones dysplasiques des tubers, mais leur implication fonctionnelle restait à montrer. Les différentes sous-unités NMDA ont une expression âge-dépendante et région-spécifique, les plus grands changements survenant au début de la vie quand l’épilepsie de la STB apparaît. Ce travail avait pour but d’étudier à l’aide de méthodes électrophysiologiques in vitro et in vivo l’expression fonctionnelle des sous-unités NMDA aberrantes et de déterminer leur rôle dans l’épileptogènese chez les souris hétérozygotes Tsc1+/- et sur le tissu humain STB post-opératoire. Nous avons pu démontrer que : i) Les souris hétérozygotes pour le gène Tsc1 sont spontanément épileptiques in vivo et in vitro dans une courte fenêtre dévelopmentale de P9 à P18. ii) Elles présentent une altération d’expression des récepteurs NMDA couche-spécifique et mTOR dépendante avec une surexpression des sous-unités GluN2C/D dans la couche 4 et 2/3 et GluN2B dans les couches 2/3. Cette expression anormale est prévenue par l’administration d’un inhibiteur de la voie mTOR, la rapamycine. iii) Les mêmes altérations d’expression des récepteurs NMDA, sont montrées sur les tissus post-opératoires, non seulement de tubers de STB mais aussi des dysplasies corticales focales (DCF), ces deux malformations ayant des similarités étiologiques et physiopathologiques. iv) La RT-PCR quantitative confirme une expression excessive de GluN2C dans le cortex de souris Tsc1+/- et sur le tissu humain des tubers et DCF. v) Les décharges épileptiques chez la souris Tsc1+/- sont générées dans la couche granulaire 4 du cortex avant de se propager vers les couches superficielles et les couches profondes, empruntant ainsi les microcircuits corticaux. vi) L’expression excessive de la sous-unité GluN2C dans le cortex contribue à l’hyperexcitabilité neuronale chez la souris Tsc1+/- et sur des tissus humains de tubers et de DCF puisque les crises et les décharges sont bloquées par les antagonistes sélectifs de GluN2C/D. vii) Les crises chez la souris Tsc1+/- suivent une séquence âge-dépendante évoluant du type «spasms-like» vers «tonic-clonic like», rappelant celle de l’épilepsie humaine, avec deux pics de haute incidence de crises à P13 et P16 correspondant chez l’homme respectivement l’âge des spasmes infantiles et celui des crises toniques. L’évolution avec l’âge du délai de propagation inter-hémisphérique pourrait contribuer à ce changement de types de crises. Ces résultats montrent donc pour la première fois qu’une happloinsuffisance pour le gène Tsc1 chez les souris Tsc1+/- sans tubers suffit à produire une altération de l’expression des récepteurs NMDA de manière mTOR dépendante et contribuer ainsi à l’épileptogènese dans la STB. La souris Tsc1+/- est le premier modèle génétique sans anomalies morphologiques présentant une épilepsie spontanée qui évolue des spasmes vers des crises toniques et tonico-cloniques. Néanmoins cette épilepsie diffère de l’épilepsie humaine de la STB par l’absence de crises focales et de pharmacorésistance, ce qui pourrait être expliqué par l’absence de tubers chez la souris Tsc1+/-. (...) / Tuberous sclerosis complex (TSC) is a genetic multisystemic disease with autosomal dominant transmission due to mutations in a gene TSC1 or TSC2 respectively which encode hamartin and tuberin proteins having an inhibitory action on the mTOR signaling pathway. Early refractory epilepsy is the most common and most deleterious neurological manifestation. The epilepsy often begins in the first year of life by infantile spasms that change in the lack of treatment to tonic or tonic-clonic seizures in age-dependent manner. Although seizures are thought to be generated in cortical tubers, epilepsy mechanisms are not well understood and treatment is often ineffective. Morphological studies showed the altered expression of glutamate receptor mRNA in the giant cells and dysplastic neurons of tubers, but their functional involvement remains unknown. The different NMDA subunits have an age-dependent and region-specific expression, the greatest changes occurring early in life when the TSC epilepsy appears. This work aimed to study the functional expression of aberrant NMDA subunits expression and their role in the epileptogenesis in heterozygous Tsc1+/- mice and post-surgical human tissue of TSC patients using in vitro and in vivo electrophysiological methods. The study reveal that: i) Heterozygous tuber-free Tsc1+/- mice show spontaneous epilepsy in vivo and in vitro in a short developmental window from P9 to P18. ii) These mice exhibit an altered NMDA receptor expression in mTOR dependent and layer-specific manner with GluN2C/D subunits overexpression in layers 4 and 2/3, and GluN2B ovexpression in layers 2/3. This abnormal NMDA receptors expression is prevented by the administration of an mTOR inhibitor, rapamycin. iii) The same alterations of NMDA receptors’ expression are shown in post-surgical tissues not only in tubers from TSC patients, but also in focal cortical dysplasia (FCD), these two malformations sharing etiological and pathophysiological similarities. iv) Quantitative RT-PCR confirms the excessive GluN2C subunit expression in Tsc1+/- mouse cortex and human tissue of tubers and DCF. v) Epileptic discharges in Tsc1+/- mice are generated in the granular layer 4 of the cortex before spreading to the superficial and then to deep layers, thus borrowing the cortical microcircuits. vi) Excessive expression of GluN2C subunit in the cortex contributes to neuronal hyperexcitability in Tsc1+/- mice, as well as in human tubers and DCF tissues, since epileptic discharges are blocked by selective GluN2C/D antagonists. vii) Seizures in Tsc1+/- mice follow the age-dependent sequence, evolving from "spasms-like" to "tonic-clonic like" thus reminding the human epilepsy, with two peaks of highest seizure incidence at P13 and P16 corresponding respectively to age of infantile spasms and of tonic seizures in human. The age-dependent evolution of interhemispheric propagation delay could contribute to this change in seizure type. These results show for the first time that TSC1 happloinsuffisancy in tuber-free Tsc1+/- mice is sufficient to produce an alteration in NMDA receptor expression in an mTOR dependent manner, and thus contributes to epileptogenesis in TSC. The Tsc1+/- mouse line is the first genetic model of TSC without morphological abnormalities presenting with early spontaneous seizures which evolves from “spasms-like” to “tonic-clonic like” seizures. However, the epilepsy in Tsc1+/- mice differs from human TSC epilepsy by the absence of focal seizures and of drug-resistance. Both could be explained by the lack of tubers in the Tsc1+/- mice. It remains to determine whether the expression of GluN2C subunit is also transitional in Tsc1+/- mice and whether other factors contribute to determine the age-dependent epilepsy. This study opens new therapeutic perspectives of TSC epilepsy targeting GluN2C subunit of NMDA receptors.

No description available.

Introducción: La fibrobroncoscopia es un procedimiento útil para el diagnóstico y tratamiento de problemas respiratorios, sin embargo, los niños tienen características anatómicas y fisiológicas que los hacen más susceptibles a complicaciones asociadas al mismo. Objetivo: Evaluar los factores asociados a complicaciones del procedimiento de fibrobroncoscopia en niños y adolescentes del Instituto Nacional de Salud del Niño San Borja. Métodos: Estudio analítico transversal a partir de una base de datos del servicio de neumología del Instituto Nacional de Salud del Niño San Borja durante el periodo junio 2018 – 2019.| Resultados: Se evaluaron 135 pacientes, de los cuales 25.9% (n=35) presentaron complicaciones asociadas al procedimiento y todas estas fueron menores. El 58.2% de los pacientes fueron varones, el 64.4% eran menores de 2 años, el 25.2% entre 2 a 5 años y un 10.4% entre 6 a 10 años. La tercera parte tenía una cardiopatía congénita. En el análisis bivariado, las complicaciones del procedimiento de fibrobroncoscopía se asociaron con el motivo de fibrobroncoscopia (p=0.002). Los pacientes con cardiopatía cianótica tuvieron cinco veces más prevalencia de complicaciones asociadas a fibrobroncoscopia luego de ajustar por variables confusoras (RP: 5.27, IC 95%: 2.29 – 12.13, p<0.05). Los pacientes que se realizaron una FB para estudio microbiológico tuvieron 2 veces más prevalencia de de complicaciones a comparación de los pacientes que se realizaron el procedimiento por otros motivos (RP: 2.92, IC 95%: 1.46 – 5.84, p<0.05). Conclusiones: Las complicaciones de la fibrobroncoscopia en niños y adolescentes son poco frecuentes y son menores. Los pacientes con cardiopatía cianótica y estudio microbiológico como motivo de fibrobroncoscopia presentan mayor prevalencia de complicaciones asociadas a este procedimiento. / Introduction: Fiberoptic bronchoscopy is a useful procedure for diagnosis and treatment of respiratory problems, however, children have anatomical and physiological characteristics that make them more susceptible to complications related to the procedure. Objective: Evaluate the factors associated with complications of the fiberoptic bronchoscopy procedure in children and teenagers. Methods: Cross-sectional analytical study based on a database of the National Institute of Child Health during the period of June 2018 - 2019. Results: Data from 135 patients were analyzed. 25.9% (n=35) presented complications associated with the procedure. 58.2% of the patients were male, 64.4% were younger than 2 years old, 25.2% between 2 and 5 years old, and 10.4% between 6 and 10 years old. The third part had a congenital heart disease. In the bivariate analysis, complications of the fiberoptic bronchoscopy procedure were associated with the reason for fiberoptic bronchoscopy (p=0.002). Patients with cyanotic heart disease have five times more prevalence of complications associated with fiberoptic bronchoscopy after adjusting for confounding variables (RP: 5.27, 95% CI: 2.29 – 12.13, p<0.05). Patients with microbiological study have two times more prevalence of complications compared to patients who underwent the procedure for other reasons (RP: 2.92, 95% CI: 1.46 – 5.84, p<0.05). Conclusions: Patients with cyanotic heart disease and a microbiological study as a reason for fiberoptic bronchoscopy have a higher prevalence of complications associated with this procedure. / Tesis

The aim of the thesis was to assess a construct validity of "Muscle Excitability Scale" in assessment of spasticity in patients with spinal cord injury. The correlation between this scale and other clinical tests evaluating various aspects of spasticity was investigated. 48 participants with symptoms of a spasticity were included in the study. The Spearman rank correlation coefficient was used for quantification of correlation between each two tests. The most significant correlation was found between the Muscle Excitability Scale and the Modified Ashworth Scale (rs=0,26 - 0,35, p<0,05). Less significant correlation was found in comparison with the Clonus Scale (rs=0,27, p<0,05) and with the SCI-SET (rs=0,25 - 0,26, p<0,05). There was no correlation between the Muscle Excitability Scale and the Penn Spasm Frequency Scale. Additionally every test was compared to each other and then the outcomes was discussed and compared to results of other similar studies. Keywords Muscle Excitability Scale, validity, spasticity, spinal cord injury, Modified Ashworth Scale, Penn Spasm Frequency Scale, Clonus Scale, SCI-SET

The aim of this paper was to define interrater reliability of "Muscle excitability scale" in assessment of lower extremities muscle spasticity in patiens with spinal cord injury. Raters were two students of 2nd grade of master study of physiotherapy. Testing was performed at Centrum Paraple o.p.s. and 48 patients took part in the research. Except the Muscle excitability scale, Modified Ashworth scale, Penn spasm frequency scale and Clonus scale were also assessed. Percentage rate of agreement and also value of kappa coefficient that state value of agreement between raters were assigned for each scale. Percent agreement for Muscle excitability scale was 54,2 % for right and 64,6 % for left lower extremity. Kappa coefficient and therefore interrater reliability of this test was assessed on 0,38 on the right side and 0,51 on the left. The results and thein comparison with other used scales are discussed in this thesis.

A prevalência de sintomas de asma, broncoespasmo induzido pelo exercício (BIE), hiperresponsividade brônquica (HRB) e alergia em atletas que praticam modalidades de alto rendimento e longa duração tem aumentado nas últimas décadas e tem sido estudada principalmente em atletas de inverno e nadadores. No entanto, a prevalência de sintomas de asma e alergia e os mecanismos inflamatórios envolvidos no BIE que ocorre em corredores de longa distância permanecem pouco conhecidos. Objetivos: O presente estudo tem como objetivo avaliar a prevalência de sintomas de asma e alergia em corredores de longa distância de elite e investigar os mecanismos inflamatórios envolvidos no BIE nos atletas sem histórico de asma. Casuística e Métodos: Este estudo foi realizado em duas fases: na Fase I, foi avaliada a prevalência de sintomas de asma e alergia em 201 corredores de longa distância, através da aplicação dos questionários ISAAC e AQUA©. Na Fase II, foram avaliados os mecanismos inflamatórios envolvidos no BIE de 40 corredores que não apresentaram sintomas de asma na Fase I e que foram selecionados aleatoriamente. Nesta fase, os atletas compareceram ao laboratório em três momentos, com intervalo máximo de duas semanas entre cada visita, e foram submetidos às seguintes avaliações 1º) escarro induzido e teste cardiopulmonar máximo, 2º) broncoprovocação por metacolina e, 3º) óxido nítrico no ar exalado (FeNO), metabólitos LTE4 e 9alfa, 11beta-PGF2 e teste de hiperventilação eucápnica voluntária (HEV). Resultados: A prevalência de sintomas de asma e alergia foi de 6,5% e 60,5%, respectivamente. Ao analisar as questões do AQUA©, observou-se alta frequência de sintomas de BIE (62,3%) e rinite (56,6%). Os sintomas de alergia não foram associados a variáveis como gênero, idade, experiência em corridas de longa distância, volume de treinamento semanal e desempenho em provas de meia maratona e maratona. Verificou-se ainda que a prevalência de BIE foi de 27,5%. Quando comparados os atletas BIE+ e BIE- não foram observadas diferenças nos valores de VEF1 absoluto, nas medidas antropométricas, nas características de treinamento e também no desempenho. Os atletas BIE+ relataram mais sintomas de alergia (p=0,03), se mostraram mais responsivos à metacolina (p=0,01), apresentaram maior porcentagem de eosinófilos no escarro (p=0,03) e níveis mais elevados de FeNO (p < 0,001*) quando comparados aos atletas BIE-. Os níveis urinários de LTE4 e 9alfa, 11beta-PGF2 basais e após 60 minutos do teste de HEV foram similares entre os grupos BIE+ e BIE-, no entanto, ao comparar os níveis destes mediadores antes e após o teste de HEV, observou-se uma diminuição nos níveis de LTE4, apenas nos atletas BIE- (p=0,04). Conclusões: Corredores de longa distância apresentam elevada prevalência de sintomas de alergia e BIE e baixa prevalência de sintomas de asma. Além disto, os atletas BIE+ referem mais sintomas de alergia, são mais hiperresponsivos à metacolina, apresentam um padrão inflamatório eosinofílico e elevados níveis de FeNO embora sem diferenças nos níveis basais dos metabólitos do mastócito / An increased prevalence of asthma and allergic symptoms, exercise-induced bronchoconstriction (EIB) and bronchial hyperresponsiveness (BHR) has been observed in elite and endurance athletes, especially winter sports athletes and swimmers. However, the occurrence of allergy symptoms and the inflammatory mechanisms involved in the EIB that occurs in long distance runners remains poorly known. Objectives: the aims of the present study were to assess the prevalence of symptoms of asthma and allergy in long distance runners and to investigate possible inflammatory mediators involved in the EIB that occurs in those without asthma history. Methods: This cross sectional study was performed in two phases. In Phase I, the prevalence of symptoms of asthma and allergy was assessed in 201 long distance runners using ISAAC and AQUA© questionnaires. In Phase II, 40 athletes were randomly selected among those who did not present asthma history and they performed the following measurements: induced sputum, cardiopulmonary exercise testing, methacholine bronchoprovocation challenge, exhaled nitric oxide (FeNO), urinary collection to quantify LTE4 and 9alfa, 11beta-PGF2 metabolites and eucapnic voluntary hyperventilation test (EVH). Results: The prevalence of asthma and allergy symptoms was 6.5% and 60.5%, respectively. In addition, we observed a high frequency of EIB symptoms (62.3%) and rhinitis (56.6%). Allergy symptoms were not associated with anthropometric characteristics, running experience, weekly training volume and best half-marathon and marathon performance. The prevalence of EIB was 27.5% and no difference in baseline lung function, anthropometric data as well as training and performance characteristics was observed between athletes with (EIB+) and without (EIB-) EIB. EIB+ athletes reported more allergy symptoms (p=0.03) and were more resposive to methacholine (p=0.01) than EIB- athletes. A higher percentage of eosinophils in the induced sputum (p=0.03) and levels of FeNO (p < 0.001*) were observed in EIB+ athletes. However, there was no difference in the urinary levels of LTE4 and 9alfa, 11beta-PGF2 either at baseline or after EVH test. Conclusions: Long distance runners have a high prevalence of allergy symptoms and EIB and a low prevalence of asthma symptoms. Moreover, EIB+ athletes report more symptoms of allergy and present airway hyperresponsiveness, eosinophilic inflammation and increased levels of exhaled nitric oxide, without difference in the baseline levels of mast cell metabolites

A prevalência de sintomas de asma, broncoespasmo induzido pelo exercício (BIE), hiperresponsividade brônquica (HRB) e alergia em atletas que praticam modalidades de alto rendimento e longa duração tem aumentado nas últimas décadas e tem sido estudada principalmente em atletas de inverno e nadadores. No entanto, a prevalência de sintomas de asma e alergia e os mecanismos inflamatórios envolvidos no BIE que ocorre em corredores de longa distância permanecem pouco conhecidos. Objetivos: O presente estudo tem como objetivo avaliar a prevalência de sintomas de asma e alergia em corredores de longa distância de elite e investigar os mecanismos inflamatórios envolvidos no BIE nos atletas sem histórico de asma. Casuística e Métodos: Este estudo foi realizado em duas fases: na Fase I, foi avaliada a prevalência de sintomas de asma e alergia em 201 corredores de longa distância, através da aplicação dos questionários ISAAC e AQUA©. Na Fase II, foram avaliados os mecanismos inflamatórios envolvidos no BIE de 40 corredores que não apresentaram sintomas de asma na Fase I e que foram selecionados aleatoriamente. Nesta fase, os atletas compareceram ao laboratório em três momentos, com intervalo máximo de duas semanas entre cada visita, e foram submetidos às seguintes avaliações 1º) escarro induzido e teste cardiopulmonar máximo, 2º) broncoprovocação por metacolina e, 3º) óxido nítrico no ar exalado (FeNO), metabólitos LTE4 e 9alfa, 11beta-PGF2 e teste de hiperventilação eucápnica voluntária (HEV). Resultados: A prevalência de sintomas de asma e alergia foi de 6,5% e 60,5%, respectivamente. Ao analisar as questões do AQUA©, observou-se alta frequência de sintomas de BIE (62,3%) e rinite (56,6%). Os sintomas de alergia não foram associados a variáveis como gênero, idade, experiência em corridas de longa distância, volume de treinamento semanal e desempenho em provas de meia maratona e maratona. Verificou-se ainda que a prevalência de BIE foi de 27,5%. Quando comparados os atletas BIE+ e BIE- não foram observadas diferenças nos valores de VEF1 absoluto, nas medidas antropométricas, nas características de treinamento e também no desempenho. Os atletas BIE+ relataram mais sintomas de alergia (p=0,03), se mostraram mais responsivos à metacolina (p=0,01), apresentaram maior porcentagem de eosinófilos no escarro (p=0,03) e níveis mais elevados de FeNO (p < 0,001*) quando comparados aos atletas BIE-. Os níveis urinários de LTE4 e 9alfa, 11beta-PGF2 basais e após 60 minutos do teste de HEV foram similares entre os grupos BIE+ e BIE-, no entanto, ao comparar os níveis destes mediadores antes e após o teste de HEV, observou-se uma diminuição nos níveis de LTE4, apenas nos atletas BIE- (p=0,04). Conclusões: Corredores de longa distância apresentam elevada prevalência de sintomas de alergia e BIE e baixa prevalência de sintomas de asma. Além disto, os atletas BIE+ referem mais sintomas de alergia, são mais hiperresponsivos à metacolina, apresentam um padrão inflamatório eosinofílico e elevados níveis de FeNO embora sem diferenças nos níveis basais dos metabólitos do mastócito / An increased prevalence of asthma and allergic symptoms, exercise-induced bronchoconstriction (EIB) and bronchial hyperresponsiveness (BHR) has been observed in elite and endurance athletes, especially winter sports athletes and swimmers. However, the occurrence of allergy symptoms and the inflammatory mechanisms involved in the EIB that occurs in long distance runners remains poorly known. Objectives: the aims of the present study were to assess the prevalence of symptoms of asthma and allergy in long distance runners and to investigate possible inflammatory mediators involved in the EIB that occurs in those without asthma history. Methods: This cross sectional study was performed in two phases. In Phase I, the prevalence of symptoms of asthma and allergy was assessed in 201 long distance runners using ISAAC and AQUA© questionnaires. In Phase II, 40 athletes were randomly selected among those who did not present asthma history and they performed the following measurements: induced sputum, cardiopulmonary exercise testing, methacholine bronchoprovocation challenge, exhaled nitric oxide (FeNO), urinary collection to quantify LTE4 and 9alfa, 11beta-PGF2 metabolites and eucapnic voluntary hyperventilation test (EVH). Results: The prevalence of asthma and allergy symptoms was 6.5% and 60.5%, respectively. In addition, we observed a high frequency of EIB symptoms (62.3%) and rhinitis (56.6%). Allergy symptoms were not associated with anthropometric characteristics, running experience, weekly training volume and best half-marathon and marathon performance. The prevalence of EIB was 27.5% and no difference in baseline lung function, anthropometric data as well as training and performance characteristics was observed between athletes with (EIB+) and without (EIB-) EIB. EIB+ athletes reported more allergy symptoms (p=0.03) and were more resposive to methacholine (p=0.01) than EIB- athletes. A higher percentage of eosinophils in the induced sputum (p=0.03) and levels of FeNO (p < 0.001*) were observed in EIB+ athletes. However, there was no difference in the urinary levels of LTE4 and 9alfa, 11beta-PGF2 either at baseline or after EVH test. Conclusions: Long distance runners have a high prevalence of allergy symptoms and EIB and a low prevalence of asthma symptoms. Moreover, EIB+ athletes report more symptoms of allergy and present airway hyperresponsiveness, eosinophilic inflammation and increased levels of exhaled nitric oxide, without difference in the baseline levels of mast cell metabolites